secwatch.observer — SEC 8-K summary
======================================

Issuer:     Azitra, Inc. (AZTR)
CIK:        0001701478
Form:       8-K
Filed at:   2026-08-12T20:55:16+00:00
Accession:  0001701478-26-000039
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Azitra Q2 net loss widens to $3.3M; pauses ATR-12, advances ATR-COSF and ATR-04
-------------------------------------------------------------------------------

- Net loss $3.3M in Q2 2026 vs $2.9M in Q2 2025; G&A up to $2.1M from $1.5M.
- Cash and cash equivalents $6.7M as of June 30, 2026.
- ATR-COSF: positive preclinical repeat-dose delivery and anti-wrinkle data in ex vivo human skin; proof-of-concept cosmetic study planned Q3 2026.
- ATR-04: continuing Phase 1/2 enrollment (6 sites incl. MD Anderson); topline data from first cohort expected Q4 2026.
- ATR-12 Netherton syndrome Phase 1b enrollment paused for capital allocation discipline.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1701478/000170147826000039/0001701478-26-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1701478/000170147826000039/aztr-20260812.htm
  HTML page:      https://secwatch.observer/filing/0001701478-26-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer